002589.SZ SHZ
Realcan Pharmaceutical Group Co., Ltd.
1W: -8.9%
1M: +2.8%
3M: +26.2%
YTD: -2.7%
1Y: +5.5%
3Y: -2.7%
5Y: -26.0%
¥3.27 ($0.49)
+0.03 (+0.93%)
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Income Trends
Revenue
$8.0B
-0.8% ▼
5Y CAGR: -25.7%
Gross Profit
$876M
+6.6% ▲
5Y CAGR: -33.7%
Operating Income
$26M
+120.2% ▲
5Y CAGR: -60.1%
Net Income
$21M
+1.5% ▲
EPS (Diluted)
$0.01
+1.5% ▲
EBITDA
$473M
+21.8% ▲
5Y CAGR: -15.8%
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Revenue | $27.2B | $21.1B | $12.3B | $8.0B | $8.0B |
| YoY Growth | -22.8% | -22.6% | -41.5% | -34.7% | -0.8% |
| Cost of Revenue | $22.2B | $17.2B | $10.6B | $7.2B | $7.1B |
| Gross Profit | $5.0B | $3.8B | $1.7B | $822M | $876M |
| Gross Margin | 18.3% | 18.2% | 13.6% | 10.2% | 11.0% |
| R&D Expenses | $9M | $12M | $23M | $40M | $10M |
| SG&A Expenses | $2.1B | $1.6B | $806M | $430M | $349M |
| Operating Expenses | $3.2B | $2.7B | $1.6B | $949M | $851M |
| Operating Income | $1.7B | $1.3B | -$1.7B | -$127M | $26M |
| Operating Margin | 6.3% | 6.2% | -13.9% | -1.6% | 0.3% |
| Interest Expense | $709M | $600M | $446M | $323M | $215M |
| Income Before Tax | $915M | $465M | -$1.7B | -$135M | $42M |
| Tax Expense | $291M | $83M | -$4M | -$167M | $551K |
| Net Income | $261M | $131M | -$1.8B | $20M | $21M |
| Net Margin | 1.0% | 0.6% | -14.9% | 0.3% | 0.3% |
| EPS (Diluted) | $0.18 | $0.09 | $-1.24 | $0.01 | $0.01 |
| EBITDA | $1.8B | $1.4B | -$961M | $388M | $473M |
| Shares Outstanding | 1.45B | 1.46B | 1.47B | 1.51B | 1.51B |